LENZ Therapeutics, Inc. Common Stock (LENZ) is a publicly traded Healthcare sector company. As of May 21, 2026, LENZ trades at $7.18 with a market cap of $216.35M and a P/E ratio of -1.97. LENZ moved +8.50% today. Year to date, LENZ is -56.31%; over the trailing twelve months it is -74.94%. Its 52-week range spans $6.61 to $50.40. Analyst consensus is strong buy with an average price target of $32.20. Rallies surfaces LENZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
LENZ Therapeutics Reports Strong Q1 Prescription Growth, Launches Phase III Trial: LENZ Therapeutics highlighted robust prescription growth for its core portfolio in Q1 2026, driven by new formulary additions and expanded market access. Management confirmed the initiation of a Phase III clinical trial for its lead pipeline candidate and outlined plans to scale commercial operations.
| Metric | Value |
|---|---|
| Price | $7.18 |
| Market Cap | $216.35M |
| P/E Ratio | -1.97 |
| EPS | $-3.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $50.40 |
| 52-Week Low | $6.61 |
| Volume | 1.22K |
| Avg Volume | 0 |
| Revenue (TTM) | $20.99M |
| Net Income | $-109.00M |
| Gross Margin | 0.00% |
6 analysts cover LENZ: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.20.